AXL and melanoma: This analysis suggests several classes of drugs such as glucocorticoid receptor (NR3C1) agonists, AXL inhibitors, PARP1 inhibitors and HDAC inhibitors as the most consistently expressed candidate drug-treatments in invasive melanoma across all studies examined.